Sector consensus Lineage Cell Therapeutics, Inc.
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Market Closed -
NYSE
16:00:00 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 0.9475 USD | -2.42% |
|
-8.89% | -43.26% |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 5.5 | +480.47% | 6 | ||||||
| 688.17 | +17.84% | 23 | ||||||
| 286.79 | +6.62% | 19 | ||||||
| 257.47 | +25.91% | 22 | ||||||
| 432.8 | +18.49% | 28 | ||||||
| 267,786.94 | +49.69% | 22 | ||||||
| 588.85 | -5.35% | 13 | ||||||
| 72.01 | -5.5% | 14 | ||||||
| 68.56 | -16.98% | 18 | ||||||
| 272.67 | +35.47% | 20 | ||||||
| 305 | +3.05% | 15 | ||||||
| 185.82 | +9.08% | 17 | ||||||
| 3.908 | -25.93% | 7 | ||||||
| 70.5 | -2.6% | 10 | ||||||
| 50.57 | +17.67% | 11 | ||||||
| 138.64 | +25.45% | 22 | ||||||
| 46.27 | +4.2% | 15 | ||||||
| 174.69 | +23.92% | 13 | ||||||
| 135.01 | +61.01% | 7 | ||||||
| 638.68 | +127.29% | 19 | ||||||
| Average | 13,610.44 | +42.49% | 16 | ||||||
| Weighted average by Cap. | 21,739.47 | +18.05% | 19 |
- Stock Market
- Stocks
- LCTX Stock
- Sector Lineage Cell Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
